AI in Predicting Polyp Pathology and Endoscopic Classification
Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Jan 12, 2025
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how artificial intelligence (AI) can help doctors better predict the types of colorectal polyps during colonoscopy, which is a procedure used to examine the inside of the colon. Currently, doctors use different methods to assess polyps based on their appearance, but these methods can be complicated and not always accurate. The goal of this trial is to see if AI can improve the accuracy of diagnosing polyps, especially those that are larger or harder to classify. By doing this, the hope is to make the process quicker and reduce the need for unnecessary treatments or follow-ups, ultimately benefiting both patients and the healthcare system.
To participate in this trial, individuals need to be at least 18 years old and be undergoing a routine colonoscopy. They should be able to understand the study and give their consent to take part. However, certain health conditions, like severe heart problems or pregnancy, may exclude someone from joining. Participants can expect to undergo a regular colonoscopy and have their polyps assessed with the help of AI technology, which could lead to more accurate diagnoses and tailored treatment plans. This trial is actively recruiting, so if you or a loved one are interested, it might be a good opportunity to consider.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Outpatients or inpatients undergoing routine colonoscopy screening at the endoscopy centers of multicenter hospitals;
- • 2. Aged 18 years or older;
- • 3. Have understanding of the study content and have signed the informed consent form.
- Exclusion Criteria:
- • 1. Gastroparesis or gastric outlet obstruction;
- • 2. Known or suspected intestinal obstruction or perforation;
- • 3. Severe chronic renal failure (creatinine clearance less than 30 mL/minute);
- • 4. Severe congestive heart failure (New York Heart Association Class III or IV);
- • 5. Currently pregnant or breastfeeding;
- • 6. Toxic colitis or megacolon;
- • 7. Poorly controlled hypertension (systolic blood pressure greater than 180 mmHg and/or diastolic blood pressure greater than 100 mmHg);
- • 8. Moderate or massive active gastrointestinal bleeding (\>100 mL/day);
- • 9. Significant psychiatric or psychological illness;
- • 10. Allergy to medications used for bowel preparation;
- • 11. Patients who have undergone colorectal surgery.
About Peking Union Medical College Hospital
Peking Union Medical College Hospital (PUMCH) is a prestigious medical institution and a leading research facility located in Beijing, China. Affiliated with the Chinese Academy of Medical Sciences, PUMCH is renowned for its commitment to advancing healthcare through innovative clinical research and high-quality patient care. The hospital plays a pivotal role in the development and execution of clinical trials across various medical disciplines, focusing on improving treatment outcomes and enhancing medical knowledge. With a multidisciplinary team of experts and state-of-the-art facilities, PUMCH is dedicated to contributing to global health advancements and fostering collaborations in the medical research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Patients applied
Trial Officials
Dong Wu, MD
Principal Investigator
Peking Union Medical College Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported